Biodesix acquires Oncimmune’s laboratory and IPN malignancy test in US
Biodesix, a lung cancer diagnostic solutions company, has acquired UK-based Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the US, to expand its blood-based lung cancer diagnostic portfolio. Oncimmune’s US commercial and lab operations, including a Clinical Laboratory Improvement Amendments (CLIA) lab in DeSoto, Kansas, has now been transferred to Biodesix. The Kansas […]